Waters Corporation
WAT
$407.74
-1.07%
Waters Corporation is a leading provider of analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools, serving the pharmaceutical, life sciences, and diagnostics industries. The company is a market leader in these niche analytical technologies, with a strong brand and installed base. In early 2026, Waters completed a transformative merger with BD's life science and diagnostics business, significantly expanding its diagnostics exposure and discovery-related life science tools. This strategic move is the central focus of the current investor narrative, as it reshapes the company's growth profile and creates both integration risks and new market opportunities.…
WAT
Waters Corporation
$407.74
Investment Opinion: Should I buy WAT Today?
Based on the analysis, I rate Waters as a Hold. The company has strong growth potential from the BD merger, but the current valuation and integration risks warrant caution. The analyst consensus is Buy with an average target of $436, implying a 5.8% upside, which is modest given the risks. The thesis is that the merger will drive long-term growth, but near-term profitability is uncertain.
Sign up to view all
WAT 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between strong growth potential and significant integration risks. The stock's valuation is stretched, but the strategic rationale for the merger is sound. The key factor is execution: if Waters can deliver on synergies and return to profitability, the stock has upside to $475. However, any misstep could lead to a decline toward $349. The stance would upgrade to bullish if the company reports two consecutive quarters of positive EPS and raises guidance. It would downgrade to bearish if the company announces further delays or impairments.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $436.00 and implied upside of +6.9% versus the current price.
Average Target
$436.00
0 analysts
Implied Upside
+6.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$349 - $475
Analyst target range
The target price range spans from a low of $349.00 to a high of $475.00, indicating a wide dispersion of 36% between the low and high, reflecting significant uncertainty around the integration and growth trajectory. The high target of $475 assumes successful execution of the BD merger, accelerating revenue growth, and margin expansion, while the low target of $349 prices in potential integration challenges, competitive pressures, or a broader economic slowdown. Recent institutional actions have been mostly neutral to positive, with no downgrades, and firms like Goldman Sachs and Guggenheim maintaining Buy ratings. The wide spread suggests that while the consensus is bullish, there is considerable debate about the pace and magnitude of the merger's benefits.
Bulls vs Bears: WAT Investment Factors
Waters presents a compelling growth story driven by the transformative BD merger, which has dramatically expanded its revenue base and market reach. The company's strong margins, solid balance sheet, and positive analyst sentiment support a bullish outlook. However, the recent net loss, premium valuation, and wide analyst target range introduce significant uncertainty. The bull case currently has stronger evidence, given the robust revenue growth and strategic rationale, but the key tension lies in whether the company can successfully integrate the acquired business and return to profitability. If integration stumbles, the stock could face substantial downside, making execution the single most critical factor in the investment debate.
Bullish
- Transformative Merger Drives 91.5% Revenue Surge: Q1 2026 revenue jumped to $1.267 billion, a 91.5% YoY increase, primarily from the BD life science and diagnostics acquisition. This expansion diversifies Waters' revenue base and opens new high-growth diagnostics markets, positioning the company for sustained top-line growth.
- Strong Profitability Metrics Despite Merger Costs: Gross margin stands at 57.8% and operating margin at 28.2%, both well above industry averages. These margins reflect the company's pricing power and operational efficiency, which should improve further as merger synergies are realized.
- Analyst Consensus is Buy with 5.8% Upside: With 23 analysts, the average target price is $436, implying a 5.8% upside from the current $412.17. The recommendation mean is 1.75 (Buy), and no recent downgrades have occurred, indicating sustained institutional confidence.
- Robust Stock Momentum and Relative Strength: WAT is up 40.4% over the past year, nearly double the S&P 500's 20.4% gain. The stock trades near its 52-week high of $420.26, with a 1-month relative strength of 7.1%, signaling strong investor demand and positive market sentiment.
Bearish
- Net Loss in Q1 2026 Raises Integration Concerns: Waters reported a net loss of $72 million in Q1 2026, with EPS of -$0.87, due to merger-related costs and interest expenses. This highlights the financial drag of the acquisition and the risk of prolonged integration challenges.
- Premium Valuation vs. Industry Peers: The trailing PS ratio is 7.14x, a 59% premium to the medical diagnostics industry average of 4.5x. The forward PE of 24.9x assumes a strong earnings recovery, leaving little room for disappointment.
- Wide Analyst Target Range Signals Uncertainty: Analyst targets range from $349 to $475, a 36% spread, reflecting significant disagreement about the merger's success and growth trajectory. This uncertainty could lead to volatile price movements.
- High PEG Ratio Suggests Overvaluation: The PEG ratio is 75.6, indicating that the stock's growth prospects are not sufficient to justify its current valuation. This metric suggests the market is pricing in aggressive future growth that may not materialize.
WAT Technical Analysis
Waters is in a strong uptrend, with the stock up 40.4% over the past year, significantly outperforming the S&P 500's 20.4% gain. The current price of $412.17 sits near the top of its 52-week range, at approximately 98% of the high of $420.26 and 46% above the low of $282.77. This positioning near the highs indicates strong momentum and investor confidence, though it also suggests the stock may be vulnerable to profit-taking or overextension in the near term.
Beta
1.18
1.18x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$283-$420
Price range past year
Annual Return
+39.9%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | +4.0% |
| 3m | +22.3% | +5.3% |
| 6m | +24.5% | +12.6% |
| 1y | +39.9% | +20.1% |
| ytd | +6.7% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Waters' revenue trajectory has been robust, with the most recent quarter (Q1 2026) showing revenue of $1.267 billion, a 91.5% increase year-over-year, driven largely by the BD merger. However, this growth is not organic; the legacy business grew at a more moderate pace, with Q4 2025 revenue of $932 million representing a 6.8% increase from the prior year. The company's revenue mix is shifting, with the new diagnostics and discovery tools segment contributing significantly, while the core Waters instrument systems and service lines continue to grow steadily. The multi-quarter trend shows accelerating growth due to the merger, but investors should monitor organic growth ex-merger to assess underlying demand.
Quarterly Revenue
$1.3B
2026-04
Revenue YoY Growth
+91.5%
YoY Comparison
Gross Margin
47.0%
Latest Quarter
Free Cash Flow
$263999000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Given that Waters reported a net loss in the most recent quarter (net income of -$72 million), I selected the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 7.14x, which is elevated compared to the broader medical diagnostics industry average of around 4.5x, representing a premium of approximately 59%. This premium is justified by the company's strong gross margins (57.8%) and operating margins (28.2%), which are well above industry norms, as well as its leading market position. However, the forward PE of 24.9x suggests the market expects earnings to recover strongly, implying that the current valuation is pricing in a successful integration of the BD business and a return to profitability.
PE
35.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 22x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to the recent merger. Waters reported a net loss of $72 million in Q1 2026, driven by merger-related costs and interest expenses, which could persist if integration is slower than expected. The company's debt-to-equity ratio of 0.58 is manageable, but the increased leverage from the acquisition adds financial risk. Additionally, the reliance on the BD business for revenue growth means that any shortfall in synergy realization could pressure margins and cash flow. Free cash flow of $264 million is positive, but it may be insufficient to cover integration costs and debt servicing if the business underperforms.